Total medical devices industry cross border deals worth $2.89bn were announced globally for March 2021, with the $1.07bn asset transaction with Lumenis being the sector’s biggest investment, according to GlobalData’s deals database.
- Embed this chart
Embed this chart into your website
Copy and paste the image source into your website to display the chart.
The value marked an increase of 381.8% over the previous month of $599.82m and a rise of 2.5% when compared with the last 12-month average of $2.82bn.
In terms of number of cross border deals, the sector saw a rise of 25.64% with 49 deals in March 2021 when compared to the last 12-month average of 39 deals.
In value terms, Middle East and Africa led the activity with cross border deals worth $1.21bn in March 2021.
Medical Devices industry cross border deals in March 2021: Top deals
The top five cross border deals accounted for 60.9% of the overall value during March 2021.
The combined value of the top five cross border deals stood at $1.76bn, against the overall value of $2.89bn recorded for the month.
The top five medical devices industry cross border deals of March 2021 tracked by GlobalData were:
1) Boston Scientific’s $1.07bn asset transaction with Lumenis
2) The $240m acquisition of Alydia Health by Organon &
3) L Catterton Partners’ $181.4m private equity deal with PHC
4) The $159m acquisition deal of Diagenode by Hologic
5) SeaSpine’s acquisition deal with 7D Surgical for $110m.
Verdict deals analysis methodology
This analysis considers only announced and completed cross border deals from the GlobalData financial deals database and excludes all terminated and rumoured deals. Country and industry are defined according to the headquarters and dominant industry of the target firm. The term ‘acquisition’ refers to both completed deals and those in the bidding stage.
GlobalData tracks real-time data concerning all merger and acquisition, private equity/venture capital and asset transaction activity around the world from thousands of company websites and other reliable sources.
More in-depth reports and analysis on all reported deals are available for subscribers to GlobalData’s deals database.